Skip to content

Study · Animal study (in vivo) · rat · 2002

4 results

Lack of involvement of mu(1) opioid receptors in dermorphin-induced inhibition of hypoxic and hypercapnic ventilation in rat pups.

Colman AS, Miller JH

Respiratory physiology & neurobiology1 Aug 2002Cited by 11 (Europe PMC)

PMID12126921 (opens in a new tab)DOI10.1016/s1569-9048(02)00030-7 (opens in a new tab)PepBankPUB-12126921
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rat pups, dermorphin inhibited the ventilatory response to hypoxia, and naloxonazine did not block this inhibition.

    In plain wordsIn rats, dermorphin reduced the breathing response to low oxygen.

    Peptide
    Dermorphin
    Outcome
    DecreaseVentilatory response to hypoxia
    Study

    ratn: not reported in source

    Conscious unrestrained Wistar rat pups
    Outcome group
    Adverse events · Respiratory
    Studied dose
    4 mg kg(-1) · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Dermorphin inhibited the ventilatory response to hypoxia, and this inhibition was insensitive to naloxonazine.
    2 context sentences
    Summary · context
    The effects of dermorphin, a mu-selective opioid agonist, on respiratory responses to altered O(2) and CO(2) during postnatal development were investigated in conscious, unrestrained Wistar rats aged 2-21 days.
    Summary · context
    Dermorphin (4 mg kg(-1)) was administered subcutaneously, and the ventilatory responses to hypoxia (11% O(2), 89% N(2)) in 2-21-day-old pups and hyperoxia (100% O(2)), and hypercapnia (8% CO(2), 92% O(2)) in 2-13-day-old pups were assessed
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rat pups, dermorphin depressed ventilation during hyperoxia through a naloxonazine-insensitive decrease in breathing frequency.

    In plain wordsIn rats, dermorphin reduced ventilation during exposure to high oxygen.

    Peptide
    Dermorphin
    Outcome
    DecreaseVentilation during hyperoxia
    Study

    ratn: not reported in source

    Conscious unrestrained Wistar rat pups
    Outcome group
    Adverse events · Respiratory
    Studied dose
    4 mg kg(-1) · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    After 5 min of hyperoxia, ventilation was the same as with air breathing except in the presence of dermorphin, when hyperoxic ventilation was depressed by a naloxonazine-insensitive decrease in frequency.
    2 context sentences
    Summary · context
    The effects of dermorphin, a mu-selective opioid agonist, on respiratory responses to altered O(2) and CO(2) during postnatal development were investigated in conscious, unrestrained Wistar rats aged 2-21 days.
    Summary · context
    Dermorphin (4 mg kg(-1)) was administered subcutaneously, and the ventilatory responses to hypoxia (11% O(2), 89% N(2)) in 2-21-day-old pups and hyperoxia (100% O(2)), and hypercapnia (8% CO(2), 92% O(2)) in 2-13-day-old pups were assessed
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rat pups, dermorphin decreased breathing frequency during hyperoxia, and this decrease was insensitive to naloxonazine.

    In plain wordsIn rats, dermorphin slowed breathing during exposure to high oxygen.

    Peptide
    Dermorphin
    Outcome
    DecreaseBreathing frequency during hyperoxia
    Study

    ratn: not reported in source

    Conscious unrestrained Wistar rat pups
    Outcome group
    Adverse events · Respiratory
    Studied dose
    4 mg kg(-1) · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    After 5 min of hyperoxia, ventilation was the same as with air breathing except in the presence of dermorphin, when hyperoxic ventilation was depressed by a naloxonazine-insensitive decrease in frequency.
    2 context sentences
    Summary · context
    The effects of dermorphin, a mu-selective opioid agonist, on respiratory responses to altered O(2) and CO(2) during postnatal development were investigated in conscious, unrestrained Wistar rats aged 2-21 days.
    Summary · context
    Dermorphin (4 mg kg(-1)) was administered subcutaneously, and the ventilatory responses to hypoxia (11% O(2), 89% N(2)) in 2-21-day-old pups and hyperoxia (100% O(2)), and hypercapnia (8% CO(2), 92% O(2)) in 2-13-day-old pups were assessed
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rat pups, dermorphin inhibited the ventilatory response to carbon dioxide, and this inhibition was insensitive to naloxonazine.

    In plain wordsIn rats, dermorphin reduced the breathing response to carbon dioxide.

    Peptide
    Dermorphin
    Outcome
    DecreaseVentilatory response to carbon dioxide
    Study

    ratn: not reported in source

    Conscious unrestrained Wistar rat pups
    Outcome group
    Adverse events · Respiratory
    Studied dose
    4 mg kg(-1) · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    The ventilatory response to CO(2) was inhibited by dermorphin in a naloxonazine-insensitive manner.
    2 context sentences
    Summary · context
    The effects of dermorphin, a mu-selective opioid agonist, on respiratory responses to altered O(2) and CO(2) during postnatal development were investigated in conscious, unrestrained Wistar rats aged 2-21 days.
    Summary · context
    Dermorphin (4 mg kg(-1)) was administered subcutaneously, and the ventilatory responses to hypoxia (11% O(2), 89% N(2)) in 2-21-day-old pups and hyperoxia (100% O(2)), and hypercapnia (8% CO(2), 92% O(2)) in 2-13-day-old pups were assessed

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.